Sexual Coercion in Breast Cancer Patients Treated With Luteinizing Hormone-Releasing Hormone Agonists (LHRHa )

NCT06840847 | Completed

• 2 other identifiers: 2023-KAEK-148Kastamonu Universty 2023/148
• Study Type: interventional
• Target: 79
• Locations: 1 country
• Sites: 1

Brief Summary

The use of luteinizing hormone-releasing hormone agonists(LHRHa) to suppress ovarian function is a common strategy for treating premenopausal, hormone receptor-positive breast cancer. However, this approach can lead to more severe and prolonged menopausal symptoms, which can further impact intimate relationships and sexual function. Sexual coercion, encompassing both overt and subtle forms of pressure, is a significant global public health concern that threatens individual well-being.

Conditions

Cancer

Keywords

breast cancer

Outcome Measures

Primary Outcomes (2)

• LHRHa

  It was examined whether patients receiving LHRHa treatment were exposed to sexual pressure.

  for 10 months

• Tamoxifen

  It was examined whether patients receiving tamoxifen treatment were exposed to sexual pressure.

  for 10 months

Study Arms (2)

LHRHa

ACTIVE COMPARATOR

In this study, included 40 patients on LHRHa. The instrument assessed partner sexual coercion in three domains: resource manipulation/sexual coercion, commitment manipulation, and threat of separation.

Behavioral: Sexual Coercion

Tamoxifen (Nolvadex)

ACTIVE COMPARATOR

In this study included 39 patients on tamoxifen. The instrument assessed partner sexual coercion in three domains: resource manipulation/sexual coercion, commitment manipulation, and threat of separation.

Behavioral: Sexual Coercion

Interventions

Sexual Coercion BEHAVIORAL

This study aimed to investigate whether patients receiving LHRHa treatment experienced sexual coercion at a higher rate than those using tamoxifen. 40 patients using LHRHa and 39 patients using tamoxifen were included in the study.

LHRHa; Tamoxifen (Nolvadex)

Eligibility Criteria

• Sex: female
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• being over 18 years of age
• willingness to participate in this study
• having received treatment for breast cancer
• having a history of breast cancer surgery
• having an active relationship with a spouse or partner.

You may not qualify if:

• having any neuropsychiatric disorder
• having any mental illness
• having a history of gynecological surgery
• currently receiving active chemotherapy or less than 3 months since completing chemotherapy
• receiving treatment for metastatic disease
• The use of selective serotonin reuptake inhibitors

Sponsors & Collaborators

• Canan Kas: lead

Study Sites (1)

Kastamonu University

Kastamonu, Merkez, 37150, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Neoplasms; Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: FACTORIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: PhD, MSc, RN, Assistant Professor

Study Record Dates

• First Submitted: February 1, 2025
• First Posted: February 21, 2025
• Study Start: January 1, 2024
• Primary Completion: October 1, 2024
• Study Completion: October 29, 2024
• Last Updated: February 25, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)